补充 发表于 2025-3-23 11:37:03

Submitted on: 28 October 2002.
Revised on: 31 December 2002.
Accepted on: 29 January 2003.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

出没 发表于 2025-3-23 17:02:01

http://reply.papertrans.cn/1/57/5680/5680-12.png

Discrete 发表于 2025-3-23 19:16:41

http://reply.papertrans.cn/1/57/5680/5680-13.png

Suppository 发表于 2025-3-23 23:33:56

Submitted on: 19 August 2000.
Revised on: 19 October 2000.
Accepted on: 04 December 2000.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

机制 发表于 2025-3-24 05:09:33

Submitted on: 28 September 2007.
Revised on: 26 January 2008.
Accepted on: 12 March 2008.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

Cumbersome 发表于 2025-3-24 07:17:49

Submitted on: 26 September 2001.
Revised on: 14 January 2002.
Accepted on: 16 February 2002.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

盘旋 发表于 2025-3-24 13:41:51

Submitted on: 13 July 2018.
Revised on: 22 October 2018.
Accepted on: 18 December 2018.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

ostensible 发表于 2025-3-24 16:13:01

Submitted on: 16 February 2013.
Revised on: 13 April 2013.
Accepted on: 03 June 2013.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

和平主义者 发表于 2025-3-24 21:55:21

http://reply.papertrans.cn/1/57/5680/5680-19.png

Prostaglandins 发表于 2025-3-25 00:14:51

Submitted on: 09 August 2004.
Revised on: 02 December 2004.
Accepted on: 15 January 2005.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS
页: 1 [2] 3 4
查看完整版本: SCIE期刊CLINICAL NEUROPHARMACOLOGY 2024/2025影响因子:0.816 (CLIN NEUROPHARMACOL) (0362-5664). (PHARMACOLOGY & PHARMACY)(药理学与药